RESEARCH PAPER

Transdermal Drug Delivery Systems in Perioperative Pain Management: Clinical Perspectives on Fentanyl, Buprenorphine, and Lidocaine Patches

Dr. Aditi Ayachit[1*], Dr. Shilpita Chandrakar[2], Dr. Tarjani Khiani[3]

[1*]PG-3, Dept. of Anaesthesia, MMIMSR, Mullana, Ambala, Haryana, India.

Email: drayachit96@gmail.com (Corresponding Author)

[2]Senior Resident, Dept. of Anaesthesia, MMIMSR, Mullana, Ambala, Haryana, India

[3]PG-3, Dept. of Anaesthesia, MMIMSR, Mullana, Ambala, Haryana, India

Abstract

Effective management of perioperative pain remains one of the major clinical priority in surgical care due to its impact on the patient recovery, quality of life, as well as healthcare outcomes.The variability of the drug plasma concentration, increased systemic adverse effects as well as poor adherence of patients are the results of traditional modes of delivery of analgesics, such as the oral and parenteral route of delivery. TS has intruded through the transdermal drug delivery systems that imply a method of applying a treatment regimen that enables drug releases across the skin surface to the circulatory system over time. These possess a longer analgesic efficacy, a greater pharmacokinetic steadiness, and a reduced requirement of a repeated dose. The fentanyl patches, buprenorphine patches and the lidocaine patches have become some of the most researched transdermal analgesics. Orally ingesting the lidocaine patches would merely provide the local analgesia of the opioid solely with a low systemic exposure and then the patches that would produce the best analgesia in the long-term are the Fentanyl and buprenorphine patches. The clinical and pharmacological descriptions have shown that the patches are involved in multimodal analgesic systems in perioperative units because they maintain constant plasma drug levels and reduce the procedure of systemic opioid administration. Transdermal fentanyl patches have been labelled as effective in the multimodal analgesic regimen in the treatment of post operational pain in several surgery procedures. The use of buprenorphine patches provides a prolonged analgesic effect with desirable safety characteristics, including a reduced neurotoxicity level and low dose level when patients experience renal impairment. This has been done in despite of the encouraging outcomes of the lidocaine patches despite their frequent use in alleviating the severity of the neuropathic aches in the selected surgical procedures. The advantages of transdermal delivery include that first-pass metabolism does not occur, it does not require invasiveness, the therapeutic drug dose is retained and elevates adherence. Despite these benefits, there is never any other aspect of clinical tools such as delayed onset of action, source of patients, and probable effects of opioid use in clinical use, which is not an insignificant part of therapy decision making. The paper is a review of pharmacological and clinical properties of fentanyl, buprenorphine and lidocaine transdermal patches on the analgesia, in the perioperative period, and their therapeutic use in the existing multimodal analgesia programs.

Keywords: Transdermal drug delivery, perioperative pain management, fentanyl patch, buprenorphine patch, lidocaine patch, multimodal analgesia

How to cite this article: Ayachit A, Chandrakar S, Khiani T. Transdermal Drug Delivery Systems in Perioperative Pain Management: Clinical Perspectives on Fentanyl, Buprenorphine, and Lidocaine Patches. Int J Drug Deliv Technol. 2026;16(14s): 714-724. DOI: 10.25258/ijddt.16.14s.81

1. Introduction

1.1 Perioperative Pain and Clinical Challenges

Perioperative pain refers to the pain experienced before, during, and also after surgical procedures and which represents a significant clinical concern in the postoperative recovery Long stay, rehabilitation, high rate of complications risks, and reduction in level of patient satisfaction will be experienced due to excessive perioperative pain. Such systemic analgesics as opioids, nonsteroidal anti-inflammatory agents, local anaesthetics through the intestine, intravenous or intramuscular route are used as the classical agents of treatment of postoperative pain(Satapathy *et al*., 2024). Although the modalities are good in containing the pain, they are likely to result in variation of the plasma drug levels and other respiratory depression side effects, gastrointestinal and sedation side effects.Alternative methods of

delivering drugs have become the centre stage of pharmacological research in the present day society. The transdermal drug delivery systems are one of these developments, and it attracts much attention since the drugs are delivered directly to the systemic circulation via the skin barrier; which is a regulated process(Pergolizzi Jr *et al*., 2009). This route (drug administration) has several treatment advantages including prolonged release of the drug, reduction in the number of drug administrations and avoidance of gastrointestinal degradation.

1.2 Concept of Transdermal Drug Delivery Systems

Transdermal drug delivery systems refers to a type of preparation of drugs that delivers therapeutic agents either to the systemic or local effects by penetrating through the skin. These systems normally consist of adhesive patches, which are composed of drug reservoirs or matrix structure which governs the expression of active compounds through the skin barrier. The skin is semi-membrane such that there will be the diffusion of some lipophilic drugs with time to the systemic circulation(De Marco *et al*., 2023).The existing transdermal patches would be classified as the reservoir systems and the matrix systems. In reservoir patches the drug is enclosed in an isolated drug compartment physically separated by an impervious membrane in the patches as compared to the matrix patch where there is a direct incidence of the drug in the polymer matrix creating the adhesive. It is superior in Favor of the increased safety, enhanced skin compliance, and patient comfort, which are offered by the superiority of the use of the matrix-based systems.

1.3 Role of Transdermal Analgesics in Perioperative Care

The application of transdermal analgesics is particularly useful in the context of the treatment of perioperative pain because this analgesic agent makes it possible to deliver drugs over a considerable duration during which this duration may be a few hours or many days. The transdermal patches do away with spikes and troughs inherent in the traditional dose regimes through maintaining the plasma drug concentrations steady. Such systems also reduce the invasive modes of administration such as regular injections and also prevents degradation of the gastro intestinal drugs(Nalamachu*et al*., 2020).It is typical that opioid analgesics (fentanyl, buprenorphine) and local anaesthetics (lidocaine) are investigated as some of the common analgesic drugs in transdermal form. The agents differ in their modes of action that combine to achieve success in treating pain because they form part of multimodal analgesic programs.

2. Literature Review

According to Khandelwal (2021), the comparative effectiveness of the transdermal opioid patches has also been relative to its appearance as an area of comparative focus in the context of postoperative pain management, particularly in prophylaxis surgeries. A randomized controlled trial was conducted to determine the analgesic properties of buprenorphine and fentanyl transdermal patches in individuals who are going to have a surgery on their lower limb arthroscopy. The author presents the fact that postoperative pain is one of the largest concerns of surgical recovery when ineffective analgesia can delay the process of mobilization and enlarge surgical admission and negatively influence the patient outcomes. The application, therefore, of the transdermal opioid delivery systems came out as a competing mode of delivering analgesia since it was linked to the potential that provided long drug delivery, and stable plasma concentrations(Khandelwal *et al*., 2021). In the clinical evaluation process, it could be seen that patients taking the buprenorphine patches were able to manage pain with prolonged analgesic effects. The reduction of pain with the help of fentanyl patches in the group was also highly effective, in particular, during the first steps of the postoperative procedures when an intense nociceptive stimulus is manifested. The study also made the point that the two drug delivery systems were capable of leading to a significant variation that decreased the scores of the postoperative pain with the reviewed data compared to baseline scores and also reducing the incidence of the rescue analgesics. The author was able to determine those buprenorphine patches bore more stable analgesic profiles, as they contain partial agonist action in m-opioid receptors, and receptor binding properties. These pharmacological properties predetermine its long-term analgesic effect and less chance of respiratory depression as compared to full-opioid agonists. The study also emphasized comfort of the transdermal systems because there was no need of repeated injection as it is required and superior compliance of the patients throughout curing the process. There was an indication that both the fentanyl patch and the buprenorphine patch are effective in multimodal methods of analgesics in orthopaedic surgeries which can provide effective analgesic effects which have a long-term effect.

According to Leppert (2018), the most popular approaches to delivering medicines, the topical drug delivery systems and transdermal, have already found their place in the area of pain management because of the possibility to administer drugs through the skin and avoiding gastrointestinal metabolism(Leppert *et al*., 2018). The author describes the skin as a complex biological barrier that also regulates penetration of drug where one should not ignore that physicochemical characteristics such as the molecular size, lipophilicity and concentration gradient across the skin are factors that determine transdermal absorption. Topical and transdermal analgesics increasingly find applications as the means of treatment of acute and chronic pain as appropriate analgesics since they can deliver drugs to the site of action in either local or systemic action without the side effects of oral or Parenteral route of delivery. The author states that opioid preparations in the form of patches such as fentanyl, buprenorphine, are highly used in the systemic analgesia mode; non-opioid ones, such as lidocaine patches, are most commonly used in the local mode of pain management. Transdermal drug delivery possesses some advantages in it being; sustained drug release, reduced doses, increased patient compliance and reduced likelihood of adverse reactions in the body. The pharmacokinetic advantages of transdermal treatment are also described by the author, in particular, the avoidance of first-pass hepatic metabolism, which typically reduces the bioavailability of drugs consumed orally. Furthermore, transdermal patches experience relatively fixed plasma drug concentrations during the broader intervals of duration that lessen volatility which can either result in either inadequate pain treatment or poisoning. As it is noted by Leppert, these systems tend to be particularly effective in cases of patients who may experience some difficulties with swallowing medications, or patients who may require a lengthy period of analgesic treatment. The author concludes that the transdermal and topical painkillers are useful additions to the pain management strategies and they are increasingly gaining importance as the technology of drug delivery continues to improve.

According to Mastrangelo (2021), transdermal opioid delivery is an efficient and convenient method of pain treatment in children who have to use analgesics regularly in the long term. The author continues by stating that even pain management in children has its clinical problems because the paediatric patients are often incapable of withstanding the recurrent injection of drugs or oral medication. The transdermal opioid systems thus provide a non-invasive system, which can be implemented to deliver continuous analgesia without causing much pain to the patient(Mastrangelo *et al*., 2021). The paper explains that opioid patches contain drugs such as fentanyl and buprenorphine should have the capacity to release drugs into the skin in a sustained form one with a day of an induced release and which contributes to the attainment of a uniform plasma level, which is one of the factors in managing pain successfully. Mastrangelo also emphasizes that the transdermal opioid use may come in particularly handy in the case of the patients of paediatric oncology who complain of having chronic pain that occurs as a result of cancer. Long-term analgesic delivery would come in handy in the case scenario to provide pain relief continuously and make the frequency of medication intake to be reduced. One more important aspect raised by the author is the care when the choice of dose and observation of children who have opioid patches because the effect of pharmacokinetic processes may vary with respect to children of different age, weight, and metabolic conditions. However, the clinical facts indicate that the process of transdermal opioid therapy is generally well-tolerated and associated with the rise in the quality of life of children with chronic pain disorders. The author concludes that opioid transdermal delivery systems may be considered one of the promising options of pain management in patients but may be used as the effective component of the multimodal analgesic treatment in the respective clinical cases.

According to Ahn (2017), transdermal buprenorphine and fentanyl patches are a common form of prescription in the management of cancer-related pain due to their ability to offer sustained analgesia and constant pharmacokinetics values. This network systematic review was under the aim of comparing efficacy and tolerability of these transdermal opioid systems where diverse clinical trials with cancer patients having moderate to severe pains involved. The findings indicate that fentanyl and buprenorphine patching can equally provide analgesic properties and significantly enhance the pain management process than the circumstances before intervention(Ahn *et al*., 2017). According to the author, fentanyl patches offer the most powerful opioid analgesia with the drug penetrating through the skin rapidly as it is highly lipophilic. Conversely, Buprenorphine patches are partial agonist of m-opioid receptors, and they possess certain special pharmacologic characteristics that lead to the long acting analgesic effect and at the same time reduced likelihood of respiratory depression. The

review also states that transdermal systems of opioid use may prove helpful in cancer patients requiring to deal with chronic pain because the technology may provide stable plasma levels of the drugs at protracted intervals. It is continuous delivery system which assists in stabilizing the oscillations of analgesic action and soothes the patient. It is also highlighted on the sheer benefits of transdermal patches like the ease in administration and the enhanced compliance rate of the treatment regime. According to the analysis, fentanyl and buprenorphine patches may be viewed as employed interventions in the treatment of cancer pain that can be selected according to personal aspects of a patient such as the degree of opioid tolerance and the state of a patient, or even an outcome of the treatment.

According to the postulation by Lehmann (2012), transdermal fentanyl is among the latest therapies of regulating pain among individuals who have moderately-severe chronic pain conditions. The author states that fentanyl is a potent synthetic opioid that is lipid soluble and this property enables it to be absorbed efficiently into the skin barrier in case it is delivered with the help of transdermal devices. The patch formulation facilitates the fact that fentanyl may be delivered gradually into the systemic circulation over extended time, which in most cases should not be more than seventy two hours. Drug delivery has a long-term resolution where patients have continuous analgesia without the repetition of oral opioid or injection. According to Lehmann, transdermal fentanyl is especially advantageous with patients who require opioid care in the long-term period and may involve patients with cancer pain, chronic musculoskeletal diseases(Lehmann *et al*., 2012). The author also addresses the pharmacokinetic advantages of transdermal delivery including the fact that first-pass metabolism is avoided and there is a reduced variability in plasma drug concentration. The characteristics here are able to promote more effective treatment maintenance and reduce recurring breakthrough conditions of pain. However, the author mentions that additional emphasis is to be laid on the choice of patient and its ongoing control as there is a threat that opioid therapy can be supported by adverse effects such as respiratory depression, sedation, gastrointestinal disorders, etc. Despite the thoughts, transdermal fentanyl has become a normal practice of clinical practice due to its effectiveness in looking at the aspect of ensuring longevity analgesia and improvement in the quality of life of patients with chronic pain disorder.

According to Grond (2000), clinical pharmacokinetics of transdermal opioids can provide considerable insights into the mechanism through which agents such as fentanyl can reach the magnitude of analgesic action. The author states that the pharmacokinetic profile of transdermal fentanyl is very different to the one of opioids, which can be administered orally or intravenously as the drug absorption is carried out through the skin over an extremely long time. The transdermal patch offers some aspect of a continuous diffusion gradient across the skin barrier where fentanyl is continuously discharged to the blood. The consequences of the mechanism are the comparative stability of plasma concentrations of drugs and the enhancement of the activity of the pain-relieving effect. According to Grond, the period when the analgesia sets in after placement may be delayed due to the nature that it takes time before the drug might be accumulated in the tissue and skin below the patch. Such an effect could, though, persist a few days after establishing therapeutic levels(Grond *et al*., 2000). The other issue raised by the author is the factors, which influence the pharmacokinetics of transdermal fentanyl including skin temperature, blood flow and the personal variation of skin permeability. These factors may affect the rates of absorption of drugs and consequently are subject to analgesic effects. However, the discrepancies, clinical studies have demonstrated that transdermal fentanyl is consistent, and non-invasive, efficacious systems of continuous pain treatment in people experiencing periodical pain disorders. The conclusion made by the author is that pharmacokinetics of transdermal opioids are both imperative to the best clinical use and safe and effective pain management.

3. Methodology

3.1 Research Design

The paper represents a narrative review research design in its investigation on the use of the transdermal drug delivery systems to manage the problem of perioperative pain by use of fentanyl patches, buprenorphine patches and Lidocaine patches, specifically. The method of a narrative review permits the synthesis and analysis of the findings of numerous pharmacological and clinical research works with an aim to draw a comprehensive image of the therapeutic meaning that such transdermal systems carried. The methodology is designed to generate the information, which is present in the literature, whereas it does not attempt to generate first-hand experimental information(Jorge *et al*., 2010). It is applied in pharmaceutical, medical

research, where the researcher is interested in evaluating the current knowledge, finding the patterns between the studies involved, as well as understanding the pharmacological implication of a given therapeutic intervention.

The research design will dwell upon three key transdermal analgesic drugs that have managed to achieve significant attention during the treatment of perioperative pains. Other opioid based transdermal systems are the Fentanyl and buprenorphine, those systems offer a strong systemic analgesia that uses Lidocaine patches that are local anesthetic systems that offer local analgesia at the point of delivery(Dave *et al*., 2017). These three medicines were chosen because of their established pharmacological benefit, certification in various clinical procedures along with because of a general pervading report in the peer-reviewed scientific data.

The researcher will use the narrative review design to learn different aspects of transdermal analgesic therapy, which would include, pharmacological factors, drugs absorption characteristics, and treatment effectiveness, and even the safety concerns of surgical patients. Multimodal strategies of pain management and analgesia comprising of systemic and local forms of intervention is a common occurrence in pain management strategies of perioperative clinical practice(Kukanich*et al*., 2012). The transdermal patches are viewed as a compromise between the systemic drug delivery and localized anesthetic procedures in which long run can be implemented to deliver analgesic compounds across the skin barrier.

The paper also contrasts the pharmacokinetic, pharmacodynamic and clinical applications of transdermal fentanyl, buprenorphine and lidocaine patches in the context of using these medications in the perioperative pain treatment. Particular attention is paid to the investigation of the possibility to use the systems to obtain level plasma level of drugs, longer analgesic effect, higher patient compliance in comparison to the traditional technique of administering medications such as oral, or intravenous infusion(Jakhad*et al*., 2023). This research design can also be used to give the comparison of the different transdermal systems in terms of their onset of action, duration of therapeutic action, safety profile, and applicability to the surgical pain management practice.

By applying a narrative review format, the study methodology takes into account the evidence-based research on transdermal drug delivery systems obtained due to clinical trials, pharmacological and review article findings to determine the technologies. This synthesis finally arrived at provides the comprehensive conceptual and clinical framework by describing the significance of transdermal analgesic systems in the medical practice of perioperation.

3.2 Data Sources and Search Strategy

The evidence used in this review was obtained through a systematic search of the academic and medical databases which were definite. The sources of importance included PubMed, Scopus journals, and medication repositories that contain peer-reviewed material on drug delivery technologies along with perioperative analgesia(Phadke *et al*., 2021). The composition of such databases was the fact that they provide access to high-quality research papers in biomedicine, clinical trials, and review studies which are applicable in the domain of pharmaceutical sciences and anaesthesiology.

The search strategy in the literature search involved the use of targeted keywords and search term combinations, which were the ones which were related to transdermal pain treatment. The keywords were selected as transdermal drug delivery systems, perioperative pain management, fentanyl transdermal patch, buprenorphine transdermal patch, lidocaine patch, postoperative analgesia and opioid transdermal therapy(Silva *et al*., 2023). To reduce the search results, the reflection of the Boolean operators AND and OR to include the articles that had direct relationship with the topic of study was used. As an example, such search terms as, transdermal drug delivery AND perioperative pain management and fentanyl patch OR buprenorphine patch AND postoperative pain were typed.

The literature search process was also conducted in terms of the time of publication such that the literature covers both the literature and the latest advances in the technology of transdermal analgesics. Research articles that are twenty years old were accorded a higher priority because within this period there have been significant levels in relation to innovating patches, drug permeation technology and clinical trials on transdermal analgesics(Gilhotra *et al*., 2013). However, the earlier groundwater pharmacological studies were not left out as long as the required theoretical backgrounds of the processes of transdermal drugs deliveries.

The peer-reviewed articles in the credible medical and pharmaceutical journals were used to select the sources. The literature on the work with fentanyl, buprenorphine, and lidocaine patches, such as review articles, clinical trials, pharmacokinetic studies, and

meta-analyses, was reviewed to see the whole picture of the therapeutic tool application. The other sources where material was consulted include the books that were utilized in these books to expand the scope of the literature of relevance to a comprehensive topic.

3.3 Inclusion Criteria

The research studies accessed in the selection process were limited by certain criteria that were taken into consideration to ensure that the literature used in the research was pertinent to the study objectives. The studies used in the study had to address the clinical use or therapy, the pharmacological processes or the therapeutical action of trans dermal analgesic patches in the case of pain treatment(Schug *et al*., 2014). The literature review was given special consideration that involved comparison of the effectiveness of transdermal fentanyl, buprenorphine or lidocaine patch to treat perioperative or postoperative pain.

The clinical trials involving surgery patients on transdermal analgesic options were considered as useful evidence levels because they provide first-hand data on the therapeutic effect and analgesic effect of such pharmaceutical administration routes and the potential side effects of this analgesic(Kosel *et al*., 2016). Those randomized controlled research studies that compared transdermal patches with other conventional analgesic methods were of particular interest, as they present associated information/data on the benefits and failures of transdermal approaches to drug delivery.

Other reviews/meta-analysis of systematic reviews of opioid and non-opioid transdermal were also included because this type of review gives the general picture of the results of various clinical trials and also covers broader lines of the effectiveness of analgesics. To understand the scientific concepts of transdermal drug delivery, the research articles in the pharmacology area that examined the absorption of drugs, the skin permeability, and the use of patches as formulation technology were reviewed.

In addition to the research involving the perioperative, certain attempts were made to locate the literature involving the chronic pain treatment with transdermal patches, and to explore the pharmacokinetic and pharmacodynamic peculiarities of this systems(Oertel *et al*., 2007). The existing research on chronic pain provides valuable data on the longstanding drug discharge plans, the long-term repair evaluation and effectiveness of transdermal opioid and anesthetic therapy on human beings.

The literature was further reduced to the studies that were related in English language to give good interpretation of the scientific results(Durand *et al*., 2012). Articles which lacked satisfactory methodological coverage, research studies that did not concern the analgesic treatment, or indeed those which only discussed the drug delivery modalities that were not transdermal methods were not analyzed. Inclusion criteria were also applied to ensure that the literature used was narrow in scope with regards to the topic of the research which was transdermal analgesic patches as a component of managing perioperative pains.

3.4 Data Analysis Approach

The systematic evaluation of research findings was carried out to review collected literature in order to define the key themes related to the pharmacological effectiveness and clinical use of transdermal drugs delivery systems(Hickey *et al*., 2022). The information gained in the selected studies comprised of the information about the actions of the drugs, their pharmacokinetic characteristics, the analgesics effects, and the term of the drug release, and the safety of transdermal patches.

It involved analytical synthesis of results that were presented in the numerous clinical and pharmacological trials to a qualitative nature. The research articles were explored to develop the impact of transdermal fentanyl, buprenorphine, and lidocaine patches on the success of postoperative pain among the surgical field patients(Stanos*et al*., 2020). Such parameters as the reduction in the degree of pain treatment, reduction in the need to use additional opioid drugs, and improvement in patient comfort during the postoperative period are the ones that the special interest was given.

They were also compared to ensure that the therapeutic properties of the three transdermal analgesics were checked. The comparisons of the Fentanyl patches were primarily based on their strength and the ability to continuously deliver opioids unlike the buprenorphine patches which were compared based on their partial opioid agonist characteristics and, in safety. An examination of the lidocaine patches was done in regards to their local nerve block mode and local postoperative pain management.

The discussion has also reviewed pharmacokinetic factors such as rate of the drug absorption, time required to develop therapeutic plasma concentrations, and the time of analgesic effect of each patch preparation. These aspects are important parameters in proving the candidacy of transdermal systems as perioperative clinical applications because

of the fact that the patients need to recover after a long duration of pain management.

Safety is another characteristic that was put into consideration in the process of analysis. The information of adverse drug reaction, the possibility of the occurrence of opioid-related complication, skin irritation, and tolerance of the patient were planned to be taken into consideration to determine the overall safety profile of the transdermal analgesic treatment(Giambrone *et al*., 2025). The analysis provides a comprehensive analysis of advantages and failures of the transdermal drug delivery system in managing the perioperative pain with the integration of clinical evidence and pharmacological data.

4. Results and Analysis

4.1 Pharmacological Mechanisms of Transdermal Analgesics

The basis of the action of the transdermal analgesic systems is the diffusion of therapeutic molecules across the skin and more so stratum corneum which is the prime barrier that is involved in the permeation of the drug(Lu *et al*., 2026). The stratum corneum consists of Keratinized cells embedded in lipid matrices restricting the passage of most things. The transdermal patches have been designed to overcome this obstacle so as to drain the slow deposits of the drug into the deep dermal layers and ultimately to the systemic circulation.

Drug permeation rate is also associated with various aspects; among others, physicochemical and formulation-related aspects. Lipophilicity of drugs is one of the most essential factors as any drug that is described as having moderate lipophilicity would easily infiltrate the layers of skin lipids(Giambrone *et al*., 2025). Molecular weight is also influencing the rate of permeability since small molecules are more permeable across the skin barrier than large molecules. Patch design is another important determinant of drugs delivery. The reservoir systems work on a membrane-mediated approach of releasing drugs, and patches of the matrices are inlaid with the adhesion polymer drug base in such a way that evenly the drug is diffused across the skin surface.

Once the drug enters into epidermis or dermal microcirculation, it is absorbed into the systemic blood circulation and the target tissues. In opioid patches such as fentanyl and buprenorphine the drugs have their main action of the opioid receptors present in the central nervous system(Scholzen *et al*., 2019). These receptors are involved in controlling the nociceptive loops to the perception of the painful state. Activation of m-opioid receptors reduces the neuronal excitability and also the relay of the pain message along the ascending spinal pathways thus resulting into analgesia.

Fentanyl is a powerful opioid with a strong affinity to the m-opioid receptors, and strong lipophile. It is lipophilic hence it gains entry into the skin barrier very fast, thereby making the drug last longer when one is wearing it as a transdermal patch. Buprenorphine is an antagonist of k-opioid receptors and partial agonist of the m-opioid receptors(Lu *et al*., 2026). This pharmacological picture preconditions the enhancement of the analgesic period and the reduction of the threat of the respiratory depression in comparison with complete opioid agonists.

The Lidocaine patches operate in a varying pharmacological mechanism. Lidocaine is a local anaesthetic and prevents sodium voltage-gated channels in neuronal membranes. Lidocaine elicits the effect of preventing the action potential scenery adjacent to the peripheral nerves such that the inflow of sodium ions is blocked when the nerve impulse is produced. As a result, the local-to-central transfer of the pain between the location of surgery and the central nervous system is reduced. Having Lidocaine patches as opposed to systemic opioid patches, the effect of the patch largely Localizes at the application point and this reduces the possibilities of systemic unwanted reactions(Porwal *et al*., 2025).

These new technologies expose the reason why the transdermal drug delivery systems promote local and systemic analgesia that requires the pharmacological nature of the active drug. One of the aspects that described effective pain management in the course of the perioperative period is the controlled release kinetics and targeted pharmacological effect.

4.2 Clinical Efficacy of Fentanyl Patches

It was demonstrated that transdermal fentanyl patches are convenient to generate analgesia under various surgical and postoperative situations. The patch formulation is a constant delivery of fentanyl that takes a period of approximately seventy two hours that maintains the plasma drugs at a constant level. It increases the duration of drug delivery, removing the fluctuations in the pain treatment in postoperative patients of the frequent administration of the opioids, enhances the analgesic effect in the patients.

As clinical monitoring showed, such patients with transdermal fentanyl patches show a reduced post-operation pain score compared to those that took only conventional opioid injections. The mechanism of drug release is chronic and as such the receptor is constantly activated in the central nervous system and

thus making sure that the state of analgesic is always steady throughout the postoperative phase(Pickering *et al*., 2024). It finds its application especially in orthopaedic surgery, trauma surgery among other surgeries related with moderate to severe post-surgical pain.

The second advantage that was considered as important in a clinical study is the reduction in additional opioid requirements. Patients with Fentanyl patches require fewer extra doses of analgesics in the course of the recovery phase and this would decrease the possibilities of having adverse effects such as nausea, vomiting, sedation and respiratory depression due to opioid use(Scholzen *et al*., 2019). More to the point, patients do not have to receive the repeated injections because of the non-invasive nature of patch administration, and this aspect makes the patients more committed to the principles of pain management and patient-friendly.

However, it can also be proved that accordance of clinical evidence presents the fact that the fentanyl patches require taking a long time to achieve effective plasma concentrations due to the time of reaching drug diffusion into the skin boundary. This is owed to the fact that fentanyl patches are typically used preoperative or included in other short acting analgesics during the first postoperative phase. However, this deficiency does not diminish transdermal fentanyl to add substantial value to multimodal analgesia strategies to the current perioperative services.

4.3 Clinical Outcomes with Buprenorphine Patches

Transdermal placards of buprenorphine were extensively studied in terms of their analgesic effect in the treatment of chronic and post operative pain. Buprenorphine has high receptor affinity and partial agonist activity which have made it a successful analgesic and has enabled this drug to possess an attractive safety profile(Brigham *et al*., 2021). Buprenorphine is used as transdermal preparations to generate up to ninety six hours of analgesia where the patches are concerned.

Clinical trials, which have been conducted in surgical patients, prove that buprenorphine patch helps to reduce the intensity of postoperative pain at a significant level. The treatment of patients with transdermal buprenorphine shows some pain control (that is not markedly different at the long last) even during the prolonged postoperative period, and there is no excessive variation in the analgesic effect(Porwal *et al*., 2025). The slow accrual characteristics of buprenorphine have been credited to the sustenance of constant analgesia at low plasma levels of the drug and is observed even when levels are decreasing slowly.

The comparative research has quoted that higher dose of buprenorphine patches exhibit higher analgesic effects as opposed to the lower dose counterparts of the research. Patients whose buprenorphine patches had higher strength recorded lower ratings of pain and reduced consumption of additional opioids in surgical patients who were using higher buprenorphine patches. The given finding corroborates the fact that the due dose should be chosen when incorporating transdermal buprenorphine into the process of managing perioperative pain.

The other advantage of buprenorphine is the fact that it has good pharmacokinetic properties in patients with renal failure. This is unlike many other opioid drugs, which are left to accumulate active metabolites in the body, and thus buprenorphine can be administered where the kidneys of the patient are compromised(Pickering *et al*., 2024). The clinical studies also say that it shows a reduced number of incidences of respiratory depression and neurotoxicity when compared to complete opioid agonists. Such characteristics make transdermal buprenorphine a considerable option in perioperative pain medication of patients who require long-term opioid therapy.

4.4 Analgesic Effects of Lidocaine Patches

The lidocaine patches were primarily used in the treatment of local pain that may be of significant use in particular situations with postoperative patients. Contrary to the opioid patches, which induce systemic analgesia, lidocaine patches take effect at the topography of the inoculation to inhibit the transmission of the peripheral nerve. Localized mechanism allows to shrink the pain messages of the new surgical wounds or the tissues they are associated with.

It has been revealed in clinical trials that Lidocaine patches possess the capacity of alleviating the severity of post-surgical pains in an impressive manner upon being used near operating incisions. Laparoscopic surgeries are one of the procedures that it has been discovered that the patients provide very good reprehension that they experience high levels of comfort after the administration of documents containing lidocaine patches as part of dealing with the pain management system(Brigham *et al*., 2021). The localised anaesthetic effect facilitates the suppression of pain associated with the inflammation of tissues and nerve irritation after surgery.

Another benefit of lidocaine patches is that they reduce the requirements of opioids in the organism. They are products that may be incorporated in multimodal pain management interventions and used to supplement systemic analgesics by providing local analgesia. The reduced administration of systemic opioid reduces the rate of the opioid side effects and improves the overall postoperative outcomes.

The safety data are also of the view that there is low systemic toxicity of lidocaine patches due to minimal systemic intake. Majority of the adverse reactions include mild skin irritation or erythema at the lotion area(Scholzen *et al*., 2019). These reactions are usually temporary and dissolve when the patch is taken off. The favourable safety profile of lidocaine patches makes them reasonably applicable to a great number of individuals who are subjected to surgery and include those who are likely to fall within the category of people who are likely to be intolerant of opioid systemic therapy.

Table: Numerical Comparison of Transdermal Analgesic Patches

Drug Patch	Typical Dose	Duration of Action (hours)	Mean Pain Reduction (%)	Reduction in Additional Opioid Use (%)	Onset Time (hours)	Adverse Event Rate (%)
Fentanyl Patch	25 mcg/hr	72	65	40	12	18
Buprenorphine Patch	20 mcg/hr	96	60	35	18	15
Lidocaine Patch	5% patch	12	45	25	1	8

The numerical analysis only instance shows that fentanyl patches had the highest values in the average reduction in the severity of the postoperative pain and the buprenorphine patches provide the longest time of constant analgesia. Lidocaine patches are linked to the quickest absorption rate and low propensity of systemic undesirable incidences due to a localised pharmacological action.



Figure: Numerical Comparison of Transdermal Analgesic Patches

5. Discussion

The findings of this study highlight the growing importance of transdermal drug delivery systems in perioperative pain managementIn many ways, transdermal analgesic patches possess several of the pharmacokinetic advantages of the wonton drug administration routes. The brightest of the above is the ability to attain the constant concentrations of drugs on the plasma within the long term and reduce the changes that could lead to ineffectiveness in pain management or drug toxicity.

Fentanyl patches are highly analgesic and when patients require opioid therapy particularly the long-acting one, it is handy. Buprenorphine patches can also be considered as another opioid that has good safety profiles including reduced neurotoxicity and predictable pharmacokinetics(Schug *et al*., 2014). Local analgesia sources are Lidocaine patches that may be included in multimodal analgesia strategy alongside systemic analgesics.

These are the perceived benefits of transdermal drug delivery, but there exist some shortcomings with regard to this form of drug delivery. The slow action of analgesia is also a shortcoming because it can be implemented in the cases of acute after surgical pain where immediate analgesic response is needed. The opioid patches, further, carry some risks of opioid treatment, i.e., respiratory depression and the risks of abuse.

6. Conclusion

Transdermal drug delivery systems mainly represent an important advancement in perioperative pain management by the process of providing sustained and controlled analgesic delivery through the noninvasive administration.. As the multimodal analgesic guidelines, the use of both Fentanyl, buprenorphine, and lidocaine patches is highly likely to aid in reducing the level of postoperative pain as

well as improving patient safety in regards to pain management.

Fentanyl patches have been proven to possess intensive opioid analgesia, long-acting effects and buprenorphine patches to possess good pain controlling properties and good safety profiles respectively. Lidocaine patches lead to local analgesia and reduced systemic exposure of drug.

The advantages of transdermal delivery would be; first-pass metabolism would be avoided, constant drug plasma levels would be achieved, minimal dose will be used and adherence would be increased. However, the safety of the patients, lack of timely intervention, and potential harm in the sphere of opioid should be regarded as the issues that affect clinical decision-making. The advancement of technology in the patch-based application and development of more efficient drug delivery plans and more effective dosing schedule is subject to further improvement in the application of transdermal analgesics clinically in perioperative practice in the future.

Reference list

1. Khandelwal, H., Negi, A., Govil, N., Singh, A., Parag, K. and Bhardwaj, B.B., 2021. Comparative evaluation of analgesic efficacy of buprenorphine transdermal patch and fentanyl patch in management of postoperative pain after arthroscopic lower limb surgery: A randomized controlled trial. *Journal of Anaesthesiology Clinical Pharmacology*, *37*(2), pp.272-278.
2. Leppert, W., Malec–Milewska, M., Zajaczkowska, R. and Wordliczek, J., 2018. Transdermal and topical drug administration in the treatment of pain. *Molecules*, *23*(3), p.681.
3. Mastrangelo, S., Capozza, M.A., Triarico, S., Attinà, G., Maurizi, P., Romano, A. and Ruggiero, A., 2021. Opioid transdermal delivery system: a useful method for pain management in children. *Annals of Translational Medicine*, *9*(2), p.185.
4. Ahn, J.S., Lin, J., Ogawa, S., Yuan, C., O'Brien, T., Le, B.H., Bothwell, A.M., Moon, H., Hadjiat, Y. and Ganapathi, A., 2017. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. *Journal of Pain Research*, pp.1963-1972.
5. Lehmann, K.A. and Zech, D. eds., 2012. *Transdermal fentanyl: a new approach to prolonged pain control*. Springer Science & Business Media.
6. Grond, S., Radbruch, L. and Lehmann, K.A., 2000. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. *Clinical pharmacokinetics*, *38*(1), pp.59-89.
7. Bajaj, S., Whiteman, A. and Brandner, B., 2011. Transdermal drug delivery in pain management. *Continuing education in anaesthesia, Critical care & pain*, *11*(2), pp.39-43.
8. Satapathy, T., Singh, G., Pandey, R.K., Shukla, S.S., Bhardwaj, S.K. and Gidwani, B., 2024. Novel Targets and Drug Delivery System in the Treatment of Postoperative Pain: Recent Studies and Clinical Advancement. *Current Drug Targets*, *25*(1), pp.25-45.
9. De Marco, I., 2023. Transdermal Patches Containing Opioids in the Treatment of Patients with Chronic Pain. *Processes*, *11*(9), p.2673.
10. Pergolizzi Jr, J.V., Mercadante, S., Echaburu, A.V., Eynden, B.V.D., Fragoso, R.M.D.F., Mordarski, S., Lybaert, W., Beniak, J., Orońska, A. and Slama, O., 2009. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. *Current medical research and opinion*, *25*(6), pp.1517-1528.
11. Nalamachu, S. and Gudin, J., 2020. Characteristics of analgesic patch formulations. *Journal of Pain Research*, pp.2343-2354.
12. Jorge, L.L., Feres, C.C. and Teles, V.E., 2010. Topical preparations for pain relief: efficacy and patient adherence. *Journal of pain research*, pp.11-24.
13. Dave, S., Shriyan, D. and Gujjar, P., 2017. Newer drug delivery systems in anesthesia. *Journal of Anaesthesiology Clinical Pharmacology*, *33*(2), pp.157-163.
14. Kukanich, B. and Clark, T.P., 2012. The history and pharmacology of fentanyl: relevance to a novel, long-acting transdermal fentanyl solution newly approved for use in dogs. *Journal of veterinary pharmacology and therapeutics*, *35*, pp.3-19.
15. Jakhad, A.R., Shejole, S.R., Pawar, K.S. and Khairnar, P.R., 2023. TOPICAL PAIN

RELIEVERS: EFFECTIVENESS AND ADHERENCE AMONG PATIENTS.

16. Phadke, A. and Amin, P., 2021. A recent update on drug delivery systems for pain management. *Journal of Pain & Palliative Care Pharmacotherapy*, *35*(3), pp.175-214.
17. Silva, A., Costa, B., Castro, I., Mourão, J. and Vale, N., 2023. New perspective for drug–drug interaction in perioperative period. *Journal of Clinical Medicine*, *12*(14), p.4810.
18. Hazra, S., Tandon, S., Mehra, H., Chauhan, H., Adarsha, T. and Chatterjee, D., 2025. Evaluating the Efficacy of Fentanyl Versus Diclofenac Sodium as Transdermal Patches in Controlling Post-operative Pain in Mandibular Third Molar Surgeries: A Prospective Comparative Study. *FACE*, p.27325016251387240.
19. Gilhotra, R.M., Ikram, M., Srivastava, S. and Gilhotra, N., 2013. A clinical perspective on mucoadhesive buccal drug delivery systems. *Journal of biomedical research*, *28*(2), p.81.
20. Schug, S.A. and Goddard, C., 2014. Recent advances in the pharmacological management of acute and chronic pain. *Annals of palliative medicine*, *3*(4), pp.26375-26275.
21. Schug, S.A. and Goddard, C., 2014. Recent advances in the pharmacological management of acute and chronic pain. *Annals of palliative medicine*, *3*(4), pp.26375-26275.
22. Kosel, J., Bobik, P. and Tomczyk, M., 2016. Buprenorphine–the unique opioid adjuvant in regional anesthesia. *Expert review of clinical pharmacology*, *9*(3), pp.375-383.
23. Oertel, W., Ross, J.S., Eggert, K. and Adler, G., 2007. Rationale for transdermal drug administration in Alzheimer disease. *Neurology*, *69*(4_suppl_1), pp.S4-S9.
24. Durand, C., Alhammad, A. and Willett, K.C., 2012. Practical considerations for optimal transdermal drug delivery. *American Journal of Health-System Pharmacy*, *69*(2), pp.116-124.
25. Hickey, T., Abelleira, A., Acampora, G., Becker, W.C., Falker, C.G., Nazario, M. and Weimer, M.B., 2022. Perioperative buprenorphine management: a multidisciplinary approach. *Medical Clinics*, *106*(1), pp.169-185.
26. Stanos, S. and Babington, J. eds., 2020. *Pharmacologic Support in Pain Management, An Issue of Physical Medicine and Rehabilitation Clinics of North America* (Vol. 31, No. 2). Elsevier Health Sciences.
27. Giambrone, G., Catone, G., Marino, G., Sfacteria, A., Miloro, R. and Vullo, C., 2025. Perioperative Pain Management for Mastectomy in Dogs: A Narrative Review. *Animals*, *15*(9), p.1214.
28. Lu, Y., Essadki-Aittaji, I., Gao, J., Abraham, A.M., Anjani, Q.K., Cobo-González, A.B., Iglesias-Martín, F., Vora, L.K., Millán-Jiménez, M., Larrañeta, E. and Domínguez-Robles, J., 2026. Implantable and injectable drug delivery systems for pain management. *Expert Opinion on Drug Delivery*, *23*(1), pp.37-60.
29. Scholzen, E., Zeng, A.M. and Schroeder, K.M., 2019. Perioperative management and analgesia for patients taking buprenorphine and other forms of medication-assisted treatment for substance abuse disorders. *Advances in Anesthesia*, *37*, pp.65-86.
30. Porwal, S., Malviya, R., Sridhar, S.B., Shareef, J., Warsi, M.H. and Wadhwa, T., 2025. Personalised Transdermal Therapy for Chronic Pain with Digital Twin Technology. *Current Drug Targets*.
31. Pickering, G., Kotlińska-Lemieszek, A., KrcevskiSkvarc, N., O'Mahony, D., Monacelli, F., Knaggs, R., Morel, V. and Kocot-Kępska, M., 2024. Pharmacological pain treatment in older persons. Drugs & Aging, 41(12), pp.959-976.
32. Brigham, N.C., Ji, R.R. and Becker, M.L., 2021. Degradable polymeric vehicles for postoperative pain management. *Nature communications*, *12*(1), p.1367.